✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Of all the peptides in the consumer longevity and wellness space, Melanotan II (MT-II) is the one that generates the loudest debate — and with good reason. Unlike recovery peptides or growth-hormone secretagogues that work on muscle and tendon, MT-II works on one of the body’s oldest and most visible signalling pathways: the melanocortin system that controls skin pigmentation, sexual function, appetite, and inflammation. Activate it systemically and you get a tan without sun exposure. You also get an uncomfortable list of side effects that the cleaner marketing sites tend to gloss over.

This guide is the honest version. MT-II is a real molecule with real mechanism, real research, and real risks. It is not FDA-approved anywhere in the world and is actively warned against by multiple regulators, including Australia’s TGA and the UK MHRA. It is also used by tens of thousands of people every year, which is why understanding the actual safety profile is more useful than either promoting or dismissing it.

You will learn what MT-II is, how it turns a tan on, the real mechanisms of action, what the research genuinely shows (short answer: almost none of it is modern, randomised, or large), how to read the mole-watching guidance that matters, how dosing protocols are structured, and how MT-II compares to close cousins like PT-141 and afamelanotide.

Melanotan II (MT-II): Benefits, Dosage, Side Effects & The Honest Science (2026)

Last updated: April 17, 2026 · Reviewed by a licensed pharmacist (MedsBase Medical Team)

What Is Melanotan II? (Definition & Background)

Melanotan II (MT-II) is a synthetic cyclic heptapeptide — seven amino acids joined in a closed ring — developed in the 1980s at the University of Arizona by Victor Hruby and Mac Hadley. Their goal was not a cosmetic product. It was a pharmacologic tool to study the melanocortin system and, potentially, to reduce skin cancer by inducing protective tanning without ultraviolet exposure. The hypothesis was straightforward: if you could darken the skin safely without UV damage, you might be able to reduce the population burden of sun-induced skin cancers.

MT-II was one of the first potent, non-selective melanocortin-receptor agonists. It activates MC1R on melanocytes (driving melanin production), MC3R and MC4R in the brain (affecting appetite and sexual arousal), and MC5R peripherally. The breadth of that activation is what gives MT-II its useful effects and also its uncomfortable side effects — every receptor the molecule hits produces a downstream consequence, desirable or not.

The pharmacology is also what makes MT-II different from its more refined successors. PT-141 (bremelanotide) was developed from MT-II specifically to isolate the MC4R arousal effect while reducing pigmentation activity, which is why PT-141 reached FDA approval (as Vyleesi) while MT-II never did. Afamelanotide (Scenesse) — another α-MSH analog — was developed and approved for erythropoietic protoporphyria, a rare photosensitivity disorder. MT-II itself was never commercialised because the safety, regulatory, and liability profile of a systemic tanning drug remained unresolved.

What happened instead is what always happens to peptides in that regulatory space: MT-II leaked into the grey market. Today it is sold worldwide as a research chemical, used by tens of thousands of people for tanning, and the subject of repeated consumer safety warnings from national regulators.

How Does MT-II Work? (Mechanism & Science)

MT-II works through simultaneous activation of all four main melanocortin receptors, with the skin-pigmentation effect driven by MC1R and the behavioural effects driven by MC3R and MC4R.

1. MC1R and Melanogenesis

When MT-II binds MC1R on melanocytes (the pigment-producing cells in the skin), it triggers a cAMP-dependent cascade that ramps up tyrosinase activity and shifts melanin synthesis toward eumelanin (the darker, more photoprotective pigment). The result is measurable darkening of the skin within 5–14 days of regular dosing, even without any UV exposure. This is the same pathway UV radiation normally triggers — MT-II just triggers it chemically.

The pigmentation effect is real and reproducible: early Phase 1 studies at the University of Arizona saw measurable tanning after just five doses over two weeks. It is not subtle.

2. MC3R/MC4R and Central Effects

The MC3R and MC4R receptors in the hypothalamus regulate appetite, energy expenditure, and sexual arousal. MT-II’s activity here produces the three most notable non-tanning effects: reduced appetite (users frequently lose 2–4 kg during a loading phase), increased sexual arousal in some users (the effect that led Palatin to develop PT-141), and mild nausea during the first several doses.

3. MC5R and Peripheral Effects

MC5R is expressed widely in peripheral tissues — skin, muscle, immune cells — with effects on sebum production, thermoregulation, and inflammatory signalling. This broad activation is why some users report oilier skin, increased body temperature, and occasional mild joint discomfort during a protocol.

Key Uses & Applications

Cosmetic Tanning (Primary Use)

This is the overwhelmingly dominant reason MT-II is sold. Users run loading protocols to establish a tan and then use maintenance dosing to preserve it. The effect is clearly visible in fair-skinned individuals who cannot tan easily with UV exposure alone — one of the reasons the molecule retains appeal despite the warnings.

Photoprotection (Theoretical)

The original research question — can chemically-induced tanning reduce skin cancer risk? — remains unanswered. Melanin does provide photoprotection, and darker pigment categorically correlates with lower non-melanoma skin cancer rates. But MT-II has never been evaluated in large-scale trials as a photoprotective intervention, so the “preventing skin cancer” framing is speculative at best.

Appetite Reduction

A minority of users run MT-II specifically for its MC4R-mediated appetite suppression. Early animal and small human studies showed modest weight loss during dosing. This is real pharmacology, but purpose-built options (GLP-1 agonists, retatrutide, lifestyle interventions) are vastly better studied, safer, and more effective.

Sexual Arousal (Cross-Over with PT-141)

MT-II’s MC4R activity produces arousal effects similar to — though less clean than — PT-141. Some users combine MT-II tanning cycles with timed sexual activity specifically to capitalise on this. If desire enhancement is the goal, however, PT-141 (bremelanotide) is the more targeted, better-studied, and FDA-approved molecule for that purpose.

Safety Profile, Side Effects & Dosage

MT-II has the least favourable safety profile of any peptide covered in this guide series. Understanding the actual signal is essential before even considering use.

Common Side Effects

• Nausea and flushing during the first 30–90 minutes after each injection, most pronounced during loading.
• Appetite suppression (2–4 kg weight loss during loading in many users).
• Facial flushing and warmth — cosmetically obvious for the first hour.
• Spontaneous erections in men during the first doses (MC4R activation).
• Dark circles under the eyes and darkening of genitals, areolas, and palms — uneven pigmentation across body sites.
• Injection-site tenderness — typical subcutaneous reaction.

Serious Concerns

• New and darkening moles — documented in multiple case series. Some moles do not lighten after discontinuation.
• Atypical melanocytic naevi — dysplastic-appearing moles that may require biopsy to rule out melanoma.
• Melanoma case reports — published cases link MT-II to melanoma diagnosis. Causation is unproven but the signal is consistent enough that regulators cite it.
• Rhabdomyolysis — rare but serious, typically with high doses (>2 mg/day).
• Renal infarction — isolated case reports.
• Blood pressure changes — typically mild; reduce dose if headache or dizziness occur.

Dosage Reference Ranges

These are observational clinical ranges, not personal recommendations.

• Starting dose: 0.25 mg SC to assess tolerance (especially nausea).
• Loading phase: 0.25–0.5 mg SC daily for 2–3 weeks.
• Maintenance phase: 0.5–1 mg SC 1–2 times per week to preserve tan.
• Maximum: 2 mg per day. Above this, risk rises disproportionately.
• Cycle length: most users cycle 8–12 weeks on, then a 4–8 week break, rather than continuous use.

Absolute Contraindications

Personal or family history of melanoma, atypical mole syndrome (>50 moles), pregnancy, breastfeeding, active cancer, uncontrolled hypertension, severe cardiovascular disease, severe kidney or liver impairment, and significant photosensitivity disorders.

What Does the Research Say?

The honest answer is: remarkably little by modern standards.

The 1996 Phase 1 Study

The Levine et al. pilot Phase 1 study (Clinical Cancer Research, 1996) demonstrated MT-II induced measurable, dose-dependent tanning at 0.025 mg/kg/day in fair-skinned volunteers. Nausea and flushing were the dominant side effects. This is the single most-cited MT-II study and the foundation of consumer-facing claims — but the study had fewer than 30 subjects and was never followed by Phase 2/3 trials.

Case Series on Hyperpigmentation and Moles

Multiple dermatology journals have published case series documenting darkening moles, new naevi formation, and atypical naevi in MT-II users. These are not controlled trials, but they are consistent and reproducible across countries.

Regulator Warnings

The UK MHRA, Australian TGA, US FDA, and EMA have all issued consumer warnings against MT-II use, typically citing the unregulated-supply and mole-change concerns. These warnings are not evidence of harm per se, but they are a useful signal about how regulators read the risk picture.

Long-Term Safety Data

Effectively none exists. Because MT-II was never formally developed past Phase 1, there are no long-term safety studies of systemic melanocortin agonism at tanning doses. Users who have been on MT-II cycles for 10+ years are self-reporting anecdotally, but the formal research base is almost empty.

MT-II vs PT-141 vs Afamelanotide

Understanding the differences among the three main melanocortin agonists in use or development is essential.

Practical takeaway. MT-II is the least refined of the three. PT-141 is MC4R-focused and available legally under prescription for a specific indication. Afamelanotide is MC1R-focused and approved for a rare genetic photosensitivity disease but not for cosmetic tanning. The three compounds are close chemical cousins that illustrate what happens when regulatory scrutiny is applied (PT-141, afamelanotide) versus not applied (MT-II).

How to Use MT-II (Reconstitution, Storage, Injection Technique)

Reconstitution

MT-II ships as lyophilised powder in 10 mg vials. Add 1 mL of bacteriostatic water for a 10 mg/mL concentration — each 0.05 mL (5 units on a 100-unit/mL insulin syringe) then delivers 0.5 mg. Some users prefer 2 mL water for a 5 mg/mL concentration so doses are easier to see on the syringe barrel. Inject the water slowly down the inside wall; swirl gently, do not shake. Solution should be clear.

Storage

Reconstituted MT-II is stable refrigerated (2–8 °C) for 2–4 weeks. Unreconstituted vials store indefinitely frozen. Protect from light.

Subcutaneous Injection Technique

• Use a 0.3–1 mL insulin syringe, 29–31 gauge, 8–13 mm needle.
• Inject subcutaneously into abdomen, thigh, or upper arm.
• Rotate sites between injections to prevent localised pigmentation patches.
• Dose in the evening to reduce daytime facial flushing visibility.
• Consider an antiemetic (ginger, ondansetron 4–8 mg) before the first 3–5 doses to blunt nausea.

Sun Exposure Pattern

MT-II increases melanin capacity but does not replace sun exposure entirely. Most users pair MT-II cycles with short, controlled UV exposure (10–20 minutes of natural sunlight or a low-UV tanning bed 2–3 times per week) to activate the extra melanin. Protocols with zero UV exposure produce a subtler tan than protocols with controlled UV.

Frequently Asked Questions

What is Melanotan II used for?

MT-II is used primarily for chemically-induced tanning, particularly in fair-skinned adults who do not tan well with UV exposure alone. Secondary uses include modest appetite suppression and sexual arousal enhancement, though purpose-built drugs exist for both. It is not FDA-approved for any use and is sold as a research compound.

Is Melanotan II safe?

MT-II is not considered safe by any major regulator. The clearest risks are mole changes (darkening of existing moles, new moles, atypical naevi), nausea, and rare case reports of rhabdomyolysis and melanoma. The honest summary: MT-II has real pharmacologic activity, a plausible mechanism for meaningful harm, and nowhere near the safety data that a mass-market skin-active drug should have. Users accept that trade-off knowingly or they do not use it.

How quickly does Melanotan II tan the skin?

Visible pigmentation typically appears within 5–14 days of daily loading doses. The response is faster and more pronounced in lighter Fitzpatrick skin types (I–III) than in darker types (IV–VI), who already have higher baseline melanin capacity.

Does MT-II work without sun exposure?

Partially. MT-II increases melanin production capacity, but melanin distribution still benefits from some UV exposure. Protocols that combine MT-II with short, controlled sun exposure produce the most pronounced and even tan. Pure no-UV protocols produce a subtler result.

How much MT-II should I use?

Clinical literature starts at 0.25 mg SC per day, loads at 0.25–0.5 mg daily for 2–3 weeks, then maintains at 0.5–1 mg 1–2 times weekly. Maximum is 2 mg/day; above this, case reports of serious side effects rise sharply. These are observational ranges, not personal recommendations.

Does MT-II cause melanoma?

Published case reports link MT-II use to melanoma diagnosis in small numbers of patients. Causation is unproven — users self-select, dermatological surveillance is uneven — but the signal is consistent enough that multiple regulators cite it. The biologically reasonable precaution is: anyone with a personal or family history of melanoma or atypical mole syndrome should not use MT-II, and every user should have a whole-body mole map with a dermatologist before and after each cycle.

Can I stack MT-II with other peptides?

Technically yes. MT-II does not directly interact with most recovery or growth-hormone peptides. The most common co-use is with PT-141 during tanning cycles (two melanocortin agonists targeting overlapping pathways — redundant and increases MC-receptor load), or with BPC-157 for recovery during training blocks (no mechanistic overlap). Stacking should always be done with medical oversight.

Is MT-II legal?

MT-II is not approved for sale or human use by the FDA, EMA, MHRA, or TGA. It is legal in most jurisdictions to possess and sell only as a “research chemical,” not for human or animal administration. Supplying MT-II for human use is illegal in the UK, Australia, and several EU countries. Check local law before purchase.

How long does a MT-II cycle last?

Most users run loading protocols of 2–3 weeks, then move to weekly or biweekly maintenance for another 2–3 months. Cycles are typically 8–12 weeks with a 4–8 week off period to let melanocortin receptor activity normalise and to allow dermatological review.

The Bottom Line — Is MT-II Worth It?

Melanotan II is a pharmacologically real, mechanistically well-understood melanocortin-receptor agonist with a genuinely useful tanning effect. It is also the least regulated, least studied, and least safe peptide in the consumer longevity space. Every major regulator has warned against it, and the case reports linking it to mole changes and rare melanoma are consistent enough that they cannot be dismissed.

For fair-skinned adults who cannot tan with UV exposure alone, who have no melanoma risk factors, who accept the dermatological risk, and who commit to baseline and follow-up mole mapping — MT-II can produce a real cosmetic result. For anyone outside that narrow profile, the risk-benefit math does not add up. Less risky options exist for almost every other goal MT-II is marketed for: PT-141 for sexual desire, retatrutide for weight loss, and dermatologically supervised tanning beds for tan.

If you are choosing to use MT-II after considering all of this, go in with eyes open. Book the mole map. Keep the doses low. Cycle instead of running continuously. Cover yourself if moles look different. And remember: of all the peptides in this guide series, MT-II is the one the safety section is longest in for a reason.

When sourcing high-purity research material, verified Melanotan II at MedsBase ships with full documentation and pharmaceutical-grade purity. To see how melanocortin agonists fit in the broader peptide toolkit, see our PT-141 guide and the cluster-wide peptide catalog.

Related Guides

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.